Yttrium-90 Radiolabeled Anti-Tac

N/A

Report date: 2025/10/20 14:38:40

Base Information

Drug NameYttrium-90 Radiolabeled Anti-Tac

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Yttrium > 90YRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionAnti-IL2RA

TargetsInterleukin-2 receptor alpha chain

Therapy Area/IndicationsLymphoma, T-Cell, CutaneousLeukemia, T-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute

Active IndicationsN/A

Inactive IndicationsLymphoma, T-Cell, CutaneousLeukemia, T-Cell

Other Information

ATC CodeN/A